BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GNI and Shanghai Genomics, Inc. to Start China Clinical Trials of Liver Drug


11/21/2007 11:36:16 AM

November 21, 2007 -- GNI Ltd received an Investigational New Drug approval of F351, its novel treatment for liver fibrosis/cirrhosis, a currently unmet need. Shanghai Genomics, the China-based affiliate of GNI, is preparing for a Phase I clinical trial of F351. Two weeks ago, Shanghai Genomics was granted a patent in China for the drug. The business offices for GNI are in Tokyo, but R&D is carried out in Fukuoka (Japan), Cambridge (UK) and China. It has an intellectual property office in San Jose, California, and its clinical trial operations are carried out through Shanghai Genomics, located in the Zhangjiang Hi-Tech Park of Shanghai. More details...

Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES